Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Amyloidosis × belantamab mafodotin × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 12 Recurrence 2 Immunoglobulin Light-chain Amyloidosis 2 Plasmablastic Lymphoma 1 Neoplasms, Plasma Cell 1 Amyloidosis 1

Interventions

Dexamethasone 5 Cyclophosphamide 4 Bortezomib 4 Melphalan 3 Lenalidomide 2 Doxycycline 2 Calcium Dobesilate 2 ixazomib 1 daratumumab 1 birtamimab 1 belantamab mafodotin 1 Vinorelbine 1 Thalidomide 1 Gemcitabine 1 Etoposide 1 Etanercept 1 Doxorubicin 1 Cisplatin 1 Antineoplastic Protocols 1 ARQ 197 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07224672 2026-03-17

ALANIS

GlaxoSmithKline

Phase 2 Not yet recruiting

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡